Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00439270 · ClinicalTrials.gov registry record · Phase 1
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT00439270 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 49 participants.
The verdict
NCT00439270, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to find the recommended doses of dasatinib and docetaxel given in combination to men with metastatic hormone refractory prostate cancer and to assess the pharmacokinetic interactions between the 2 drugs.
Interventions
- DRUG Docetaxel
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2007-07 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00439270
The ClinicalTrials.gov registry entry for NCT00439270 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00439270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00439270 about?
NCT00439270 is a clinical study titled "Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer". The purpose of this study is to find the recommended doses of dasatinib and docetaxel given in combination to men with metastatic hormone refractory prostate cancer and to assess the pharmacokinetic interactions between the 2 drugs.
What is the current status of trial NCT00439270?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2007-07. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00439270?
The interventions under investigation include: Docetaxel (DRUG), Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00439270?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.